识别与肺腺癌的预后相关的溶解体基因
Houqiang Li1,2, Xinyu Sha1,2, Wenmiao Wang1,2
1Department of Thoracic Surgery, Nantong Key Laboratory of Translational Medicine in Cardiothoracic Diseases, Research Institution of Translational Medicine in Cardiothoracic Diseases in Affiliated Hospital of Nantong University, Nantong, China.
Translational lung cancer research
|August 14, 2023
概括
这项研究确定了四个关键基因 (GATA2,TFAP2A,LMBRD1,KRT8) 作为肺腺癌 (LUAD) 的预后生物标志物. 这些生物标志物形成了一个可靠的模型,预测患者的结果和对治疗的反应.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 肺腺癌 (LUAD) 是最常见的肺癌亚型.
- 尽管取得了进展,但LUAD的复发率很高,需要改进预后工具.
研究的目的:
- 为了确定LUAD的新型预后生物标志物.
- 开发一个预测模型来预测LUAD患者的结果和治疗反应.
主要方法:
- 利用来自TCGA和GEO数据库的RNA-seq数据.
- 使用考克斯回归和差异性基因表达分析识别了差异性预后性溶解体相关基因 (LRG).
- 使用LASSO和Kaplan-Meier分析构建了一个预后模型;通过qPCR,西斑和HPA验证了基因表达.
主要成果:
- 四个基因 (GATA2,TFAP2A,LMBRD1,KRT8) 被选为LUAD的预后生物标志物.
- 开发的风险模型证明了可靠的预测准确性.
- 风险评分和瘤阶段被确定为独立的预后因素.
- 风险组之间观察到免疫检查点抑制剂和药物敏感性的不同表达.
结论:
- 使用GATA2,TFAP2A,LMBRD1和KRT8.8构建了LUAD患者的显著预后模型.
- 这些生物标志物为改善LUAD患者管理和个性化治疗策略提供了潜力.
相关概念视频
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K


